Insurtech Eye — Insurance Technology News

Amwins Launches Exclusive Global Clinical Trials Insurance Solution with Lloyd’s Partnership

By Lauren Towner · 20 November 2026

In brief: Amwins has launched a new clinical trials insurance product in partnership with Lloyd’s, offering pre-licensed coverage in 115+ countries with same-day quoting for international research sponsors.

Key facts
Coverage Limit$25 million
Geographic Reach115+ countries
Service SpeedSame-day quoting and issuance
PartnerLloyd’s syndicate
Press Release: Amwins Launches Exclusive Global Clinical Trials Insurance Solution with Lloyd’s Partnership | Featured Image by FF News

Amwins has launched an exclusive clinical trials insurance solution to address the regulatory hurdles and administrative friction inherent in international medical research. By utilizing Lloyd’s paper pre-licensed in over 115 countries, the product simplifies global placements for retail brokers, offering a single-policy alternative to the fragmented local coverage typically required for multi-territory studies.

What was announced

The new solution, housed within Amwins’ Brokerage division, was developed in collaboration with a prominent Lloyd’s syndicate specializing in the clinical trials market. It is designed to meet the mandatory regulatory requirements for clinical trials in most global territories, where insurance is often the final prerequisite before a study can commence. The product is available exclusively through Amwins brokers and provides a comprehensive suite of coverages, including clinical trials indemnity, no-fault compensation, and clinical testing liability. Additionally, the policy encompasses public, products, and professional liability, alongside medical malpractice coverage.

A primary feature of the offering is its geographical reach, with the underlying paper pre-licensed in more than 115 countries. This allows for a single-placement approach even when trials span multiple jurisdictions. The product supports a wide spectrum of clinical research exposures, ranging from first-in-man Phase I trials through to Phase IV research. It is also tailored for contract research organizations (CROs), investigator-led studies, and university-based clinical trial programs. From a capacity standpoint, the solution offers limits of up to $25 million with no class limitations. Amwins has also prioritized speed of execution, promising same-day quoting and the immediate issuance of certificates and policy documentation.

The companies involved

Amwins is the largest independent wholesale distributor of specialty insurance products in the United States. The firm acts as a critical intermediary in the insurance value chain, connecting retail agents with specialized markets and underwriting capacity that might otherwise be inaccessible. With a significant footprint in the brokerage space, the company manages a diverse portfolio of niche risks across property, casualty, and professional lines.

The Lloyd's Corporation, often referred to as the Lloyd’s of London market, provides the foundational licensing and capacity for this new solution. As a global insurance and reinsurance marketplace, Lloyd’s operates through a unique structure of syndicates that underwrite specialized risks. Its extensive global licensing network is a key asset for international placements, allowing syndicates to write business in over 200 territories. This partnership leverages that global reach to solve the specific licensing gaps that often delay clinical research projects when handled by standard domestic carriers.

What FF News has reported before

Amwins has recently focused on integrating advanced technology into its operational framework. FF News previously reported on how Amwins Scales AI Strategy with Anthropic's Claude Integration Across 8,000 Employees, highlighting the firm's commitment to using artificial intelligence to enhance its internal data capabilities.

The Lloyd’s market has also seen significant activity regarding new capacity and operational resilience. FF News covered the launch of a new vehicle in the market when Aon and Blackstone Launch Cortina: A Revolutionary New Lloyd's Syndicate for Reinsurance. Additionally, the market's infrastructure has been a point of discussion, such as when LMA Operations Director Joe Brace on Microsoft Outage and London Market Resilience detailed the sector's response to systemic technical disruptions. Other entities have also sought to leverage the Lloyd's ecosystem, as seen when Boost Insurance Becomes Lloyd’s Coverholder and Expands Reinsurance Panel with Nine Global Partners.

What this means from an insurtech perspective

From an insurance perspective, this announcement highlights a shift toward reducing "administrative drag" in highly regulated specialty lines. Clinical trials are notoriously difficult to underwrite due to the varying legal requirements for "no-fault" compensation across different borders. By automating the issuance process to a "same-day" standard, Amwins is challenging the traditional, manual underwriting timelines that have long plagued the life sciences sector. This puts pressure on incumbent carriers who rely on legacy core systems that cannot easily handle multi-jurisdictional compliance checks in real-time. For MGAs and brokers, the ability to consolidate a global study into a single placement significantly reduces the risk of coverage gaps and lowers the operational cost of managing international programs.

Frequently asked questions

What is included in the Amwins clinical trials insurance solution?

The solution includes clinical trials indemnity, no-fault compensation, and clinical testing liability. It also provides public, products, and professional liability alongside medical malpractice coverage, written on paper pre-licensed in over 115 countries.

How fast can I get a quote for clinical trials insurance?

Amwins offers same-day quoting and same-day issuance of certificates and policy documents. This rapid turnaround is designed to help sponsors clear regulatory hurdles quickly so that clinical studies can begin without administrative delays.

What types of research does the Amwins clinical trials program support?

The program supports a wide range of clinical research, including Phase I through Phase IV research, Contract Research Organization (CRO) exposures, investigator-led studies, and university clinical trial programs with no specific class limitations.

About the companies

Amwins

Website · 8 stories on FF News since 2025

Previously on FF News:

Lloyd's Corporation

18 stories on FF News since 2023

Previously on FF News:

Companies in this story: Amwins, Lloyd's Corporation

People in this story: Tom Dillon

More from News